Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 1997

View Archived Issues

Nippon Kayaku isolates novel antitumor agents

Antitumor indane derivatives from Taiho

Pola discloses antitumor/immunosuppressive agents

5-HT2 antagonists/5-HT reuptake inhibitors described by Yamanouchi

Meiji Seika discloses new cardiotonic agents

Esters of estrogenic compounds from Lilly

Placebo associated with improvement and side effects in treatment of BPH

Novel aggregation pathway identified

Optimal dose of sertraline for premature ejaculation

DiagnoCure licenses growth factor derivatives for cancer diagnosis/therapy

Mechanism of HCV resistance to interferon discovered

Matrix issued U.S. patent for drug delivery technology; preclinical data presented

Amgen and Roche extend EU collaboration on G-CSF products

Generic minoxidil receives FDA approval

Isis receives contract for combinatorial antibacterial drug research

Another minoxidil generic approved in U.S. for women

Supplemental BLA submitted in U.S. for Proleukin

Oxford Molecular Group and ImmunoGen join efforts in humanized antibody development

Focus on sildenafil for erectile dysfunction

CVT-124 enters phase II trials for CHF

HIV viral replication halted using Eukarion's antibody lipidation technology

Potential BPH therapy from Abbott

New bladder-selective M3 antagonist reported by Yamanouchi

ImClone reports research results from its anti-flk-1 monoclonal antibody program

Biogen reveals new cell adhesion inhibitor

Potent and selective ETA antagonist from SKB

C225 effective in mouse model of human bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...